Literature DB >> 30872149

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Ali Alikhan1, Christopher Sayed2, Afsaneh Alavi3, Raed Alhusayen3, Alain Brassard4, Craig Burkhart5, Karen Crowell6, Daniel B Eisen4, Alice B Gottlieb7, Iltefat Hamzavi8, Paul G Hazen9, Tara Jaleel10, Alexa B Kimball11, Joslyn Kirby12, Michelle A Lowes13, Robert Micheletti14, Angela Miller8, Haley B Naik15, Dennis Orgill16, Yves Poulin17.   

Abstract

Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nd:YAG; acne inversa; adalimumab; biomarkers; carbon dioxide laser; clindamycin; comorbidities; ertapenem; finasteride; guidelines; hidradenitis suppurativa; infliximab; laser; lifestyle modification; microbiome; oral contraceptive pills; rifampin; spironolactone

Mesh:

Substances:

Year:  2019        PMID: 30872149      PMCID: PMC9131892          DOI: 10.1016/j.jaad.2019.02.068

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   15.487


  118 in total

1.  Methotrexate is of limited value in the treatment of hidradenitis suppurativa.

Authors:  G B E Jemec
Journal:  Clin Exp Dermatol       Date:  2002-09       Impact factor: 3.470

2.  Treatment of hidradenitis suppurativa with etanercept injection.

Authors:  David R Adams; Jessica A Yankura; Anneli C Fogelberg; Bryan E Anderson
Journal:  Arch Dermatol       Date:  2010-05

3.  Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients.

Authors:  V Bettoli; S Zauli; A Borghi; G Toni; S Minghetti; M Ricci; A Virgili
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-03-02       Impact factor: 6.166

Review 4.  Local wound care and topical management of hidradenitis suppurativa.

Authors:  Afsaneh Alavi; Robert S Kirsner
Journal:  J Am Acad Dermatol       Date:  2015-11       Impact factor: 11.527

5.  Four-weekly infliximab in the treatment of severe hidradenitis suppurativa.

Authors:  B Moriarty; Z Jiyad; D Creamer
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

6.  Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.

Authors:  W P Gulliver; G B E Jemec; K A Baker
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-05-24       Impact factor: 6.166

Review 7.  The Role of Androgens and Estrogens in Hidradenitis Suppurativa - A Systematic Review.

Authors:  Peter Theut Riis; Hans Christian Ring; Lotte Themstrup; Gregor Borut Jemec
Journal:  Acta Dermatovenerol Croat       Date:  2016-12       Impact factor: 1.256

8.  Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support.

Authors:  F W Danby; G B E Jemec; W Ch Marsch; M von Laffert
Journal:  Br J Dermatol       Date:  2013-05       Impact factor: 9.302

9.  Evaluation of isotretinoin treatment of hidradenitis suppurativa.

Authors:  C H Dicken; S T Powell; K L Spear
Journal:  J Am Acad Dermatol       Date:  1984-09       Impact factor: 11.527

10.  Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab.

Authors:  Ian Gorovoy; Adar Berghoff; Laura Ferris
Journal:  Case Rep Dermatol       Date:  2009-10-27
View more
  28 in total

1.  Complementary and Alternative Medicine Use in Patients With Hidradenitis Suppurativa.

Authors:  Kyla N Price; Alyssa M Thompson; Omar Rizvi; Aleksi J Hendricks; Afsaneh Alavi; Jennifer L Hsiao; Vivian Y Shi
Journal:  JAMA Dermatol       Date:  2020-03-01       Impact factor: 10.282

2.  Impact of a hidradenitis suppurativa patient decision aid on treatment decision making: A randomized controlled trial.

Authors:  Donna McLean; Olivia McBride; Tanja Samardzic; Mia Sisic; Robert P Dellavalle; Jerry Tan
Journal:  JAAD Int       Date:  2020-10-29

3.  An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series.

Authors:  Pelin Esme; Aysenur Botsali; Gulsen Akoglu; Ercan Caliskan
Journal:  Skin Appendage Disord       Date:  2022-02-09

Review 4.  The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment.

Authors:  Marisa E Luck; Joy Tao; Eden P Lake
Journal:  Am J Clin Dermatol       Date:  2022-09-18       Impact factor: 6.233

5.  Diagnosis and management of hidradenitis suppurativa in women.

Authors:  Erin K Collier; Ram K Parvataneni; Michelle A Lowes; Haley B Naik; Martin Okun; Vivian Y Shi; Jennifer L Hsiao
Journal:  Am J Obstet Gynecol       Date:  2020-09-24       Impact factor: 8.661

Review 6.  Hidradenitis Suppurativa: Surgical and Postsurgical Management.

Authors:  Marco Manfredini; Federico Garbarino; Laura Bigi; Giovanni Pellacani; Cristina Magnoni
Journal:  Skin Appendage Disord       Date:  2020-05-14

7.  A Call to Accelerate Hidradenitis Suppurativa Research and Improve Care-Moving Beyond Burden.

Authors:  Haley B Naik; Michelle A Lowes
Journal:  JAMA Dermatol       Date:  2019-09-01       Impact factor: 11.816

8.  Provider perspectives on the management of hidradenitis suppurativa in pregnancy - A survey study.

Authors:  Erin K Collier; Kyla N Price; Tristan Grogan; Jennifer M Fernandez; Justine R Seivright; Raed Alhusayen; Afsaneh Alavi; Iltefat H Hamzavi; Michelle A Lowes; Martina J Porter; Vivian Y Shi; Jennifer L Hsiao
Journal:  Int J Womens Dermatol       Date:  2020-12-11

9.  Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.

Authors:  Elisa Molinelli; Valerio Brisigotti; Oriana Simonetti; Claudia Sapigni; Giovanni Marco D'Agostino; Giulio Rizzetto; Alfredo Giacchetti; Annamaria Offidani
Journal:  Dermatol Ther       Date:  2022-03-18       Impact factor: 3.858

Review 10.  [Hidradenitis suppurativa /acne inversa-surgical options, reconstruction and combinations with drug therapies-an update].

Authors:  P Cramer; S Schneider-Burrus; M Kovács; L Scholl; M Podda; F G Bechara
Journal:  Hautarzt       Date:  2021-07-06       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.